Background: Rheumatoid arthritis (RA) is a type of difficult-to-cure arthralgia with a worldwide prevalence. It severely affects people’s living standards. For a long time, bee venom has been used to treat RA and has shown good results. Melittin is the main active component of bee venom used for RA treatment, but the molecular mechanism of melittin in RA treatments remains unclear. Methods: Potential melittin and RA targets were obtained from relevant databases, and common targets of melittin and RA were screened. The STRING database was used to build the PPI network and screen the core targets after visualization. The core targets were enriched by Gene Ontology functional annotation and Kyoto Encyclopedia of Genes and Genomes pathway. Finally, the binding of melittin to target proteins was evaluated through simulated molecular docking, which verified the reliability of the prediction results of network pharmacology. Results: In total, 138 melittin targets and 5795 RA targets were obtained from relevant databases, and 90 common targets were obtained through intersection. Eighteen core targets, such as STAT3, AKT1, tumor necrosis factor, and JUN, were screened out. Enrichment analysis results suggested that melittin plays an anti-RA role mainly through tumor necrosis factor, interleukin-17, toll-like receptors, and advanced glycation end products–RAGE signaling pathways, and pathogenic bacterial infection. Molecular docking results suggested that melittin has good docking activity with core target proteins. Conclusion: RA treatment with melittin is the result of a multi-target and multi-pathway interaction. This study offers a theoretical basis and scientific evidence for further exploring melittin in RA therapy.

Royal jelly acid (10-HDA), an unsaturated fatty acid unique to royal jelly, exhibits a diverse range of biological activities, including hypoglycemic, anti-inflammatory, and anticancer properties. In recent years, the increasing demand for natural product supplements as health enhancers has led to a significant rise in the consumption of royal jelly products for daily wellness. Consequently, the market for royal jelly supplements has expanded considerably. Understanding the mechanisms underlying the biological activities of royal jelly acid is crucial for optimizing its therapeutic applications and guiding the development of innovative royal jelly-based products. This review consolidates current research on the preparation, metabolism and potential pharmacological roles of royal jelly acid in managing cancer, inflammatory disorders, and glucolipid metabolic diseases and explores the molecular mechanisms driving these effects. Future research should leverage advanced analytical techniques to uncover the intricate mechanisms of royal jelly acid’s actions, paving the way for its broader integration into healthcare and clinical settings.

Background: Rheumatoid arthritis (RA) is an erosive-destructive inflammation of the joints, and the chronic, long-term stiffness and deformation induced by RA are some of the symptoms of arthritis that are difficult to treat. Dexamethasone (DEX) and melittin (MLT) are two interesting anti-inflammatory substances, both of which possess anti-inflammatory effects exerted through the suppression of the immune system. The purpose of this study was to explore the role of MLT in the treatment of RA by DEX as well as to clarify the influence of MLT on the efficacy and side effects of DEX.Method: The rats were injected with Complete Freund’s Adjuvant (CFA) to induce arthritis, followed by treatment with different doses of DEX and/or MLT. The relevant indexes of paw inflammation were determined, and the appetite, growth status, arthritis status, cytokine levels, and organ coefficient of the rats were evaluated. In addition, the paraffin sections of the joint tissues were prepared to analyze the pathological changes.Result: DEX exhibited side effects, notably hindering feed intake and growth, and inducing immune organ lesions in the rats. MLT significantly reduced the side effects of DEX and promoted its efficacy. DEX in combination with MLT demonstrated a synergistic efficacy in RA treatment, showing advantages in detumescence reduction, pro-inflammatory cytokine inhibition, and joint internal pathological improvement.Conclusion: Thus, MLT promoted the efficacy of DEX in adjuvant RA treatment in rats, offering an approach to reduce the use dosage and side effects of DEX.

Plastics and pesticides are commonly used and often coexist in the environment. As pollinating insects, honeybees are simultaneously exposed to both these toxins. However, there has been no study on the toxic effects of nano-polystyrene plastics (nanoPS) and cyfluthrin (Cy) on the Apis cerana cerana Fabricius until now. This study found that nanoPS did not significantly impact the mortality of Apis cerana cerana but could reduce cyfluthrin-induced mortality. Additionally, nanoPS caused damage to the honeybee gut and hindered the development of the hypopharyngeal glands, whereas cyfluthrin did not produce these pathological changes. Concerning the detoxification-related genes, the two toxins alone and in combination significantly promoted the expression of P450 9E2 and Cyp9Q3 genes, and the upregulation trend was found more significant for the combination. Regarding immune gene expression, exposure to a single toxin or both toxins significantly down-regulated the abaecin gene, but only exposure to nanoPS significantly decreased apidaecin expression. The changes in metabolites and metabolic pathways in honeybees after ingesting nanoPS were also studied. This study highlights the toxicity of nano-microplastics and Cy alone and in combination to Apis cerana cerana Fabricius and provides new insights into the potential ecological risks of nanoPS.